Financial reports
20-F
2023 FY
Annual report (foreign)
21 Mar 24
20-F
2022 FY
Annual report (foreign)
16 Mar 23
20-F
2021 FY
Annual report (foreign)
21 Mar 22
20-F
2020 FY
Annual report (foreign)
30 Mar 21
20-F
2019 FY
Annual report (foreign)
31 Mar 20
20-F
2018 FY
Annual report (foreign)
26 Mar 19
20-F
2017 FY
Annual report (foreign)
26 Mar 18
Current reports
6-K
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
16 Apr 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
27 Mar 24
6-K
Regulatory decision in Japan represents first global approval for VYVGART in ITP
26 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years
8 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP
20 Feb 24
6-K
Current report (foreign)
18 Jan 24
6-K
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
8 Jan 24
Registration and prospectus
S-8
Registration of securities for employees
27 Sep 23
424B5
Prospectus supplement for primary offering
20 Jul 23
424B5
Prospectus supplement for primary offering
17 Jul 23
424B5
Prospectus supplement for primary offering
25 Mar 22
424B5
Prospectus supplement for primary offering
22 Mar 22
S-8
Registration of securities for employees
29 Jul 21
F-3ASR
Automatic shelf registration (foreign)
29 Jul 21
424B5
Prospectus supplement for primary offering
4 Feb 21
FWP
Free writing prospectus
2 Feb 21
424B5
Prospectus supplement for primary offering
1 Feb 21
Proxies
No filings
Other
CT ORDER
Confidential treatment order
9 May 19
EFFECT
Notice of effectiveness
13 Dec 17
CORRESP
Correspondence with SEC
11 Dec 17
CORRESP
Correspondence with SEC
11 Dec 17
UPLOAD
Letter from SEC
14 Nov 17
CT ORDER
Confidential treatment order
18 May 17
CORRESP
Correspondence with SEC
17 May 17
EFFECT
Notice of effectiveness
17 May 17
UPLOAD
Letter from SEC
17 May 17
CORRESP
Correspondence with SEC
16 May 17
Ownership
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G
Artisan Partners Limited Partnership
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BlackRock Inc.
1 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 23
SC 13G/A
Artisan Partners Limited Partnership
10 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
SC 13G
BlackRock Inc.
11 Mar 22
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 22